Cingulate Inc. is a clinical-stage biopharmaceutical company focused on innovative once-daily stimulant formulations for ADHD and anxiety treatment. Despite substantial losses totaling over $132 million since inception, the firm is advancing its lead candidate CTx-1301 with an NDA accepted by the FDA and a target regulatory decision date in May 2026. The company remains pre-revenue, heavily reliant on equity and debt issuances for funding, with approximately $11 million in cash at the end of 2025. Investors should monitor the upcoming FDA decision and the company's ability to secure continued capital to sustain operations.